OBJECTIVE -To examine the efficacy and safety of rimonabant, a selective cannabinoid receptor type-1 antagonist, in patients with type 2 diabetes receiving insulin monotherapy.
T he increasing prevalence of obesity is contributing to a type 2 diabetes epidemic (1) . Current standard of care of type 2 diabetes targets control of lipid and blood pressure levels, as well as glucose control (1) (2) (3) . Most classes of antidiabetes agents are associated with weight gain, spurring research into therapeutic agents that improve both weight and glycemia, along with favorable effects on other comorbidities (4) .
The endocannabinoid system contributes to energy homeostasis and lipid and glucose metabolism regulation (5) . Treatment with the selective cannabinoid type 1 (CB 1 ) receptor antagonist rimonabant improves multiple cardiometabolic risk factors in overweight/obese patients (6 -10) as well as glycemic control in patients with drug-naïve type 2 diabetes (SERENADE study) (11) or disease suboptimally controlled on sulfonylurea/ metformin (RIO-Diabetes study) (8) .
The ARPEGGIO study evaluated once-daily 20 mg rimonabant on glycemic control in patients with type 2 diabetes inadequately controlled on insulin monotherapy (a population considered therapeutically challenging). It should be noted that the clinical development of rimonabant has stopped and the compound withdrawn from the market.
RESEARCH DESIGN AND
METHODS -Eligible patients were aged Ն18 years, with type 2 diabetes, screening A1C Ն7%, and receiving insulin monotherapy for Ն3 months (Ն30 units/day for Ն4 weeks). Type 1 diabetes was excluded with C-peptide Ͻ1.0 ng/dl.
Patients with a history of depression and/or past/current antidepressant treatment were included. Institutional review boards and independent ethics committees at each center approved the protocol. The study was conducted in accordance with the Declaration of Helsinki. Patients provided written informed consent.
Following a 14-day screening period, patients were randomized (1:1; stratified by A1C level) to placebo or 20 mg rimonabant (oral, once daily before breakfast) for 48 weeks. Patients were advised to follow a controlled diet and increase physical activity. The total daily insulin dose (TDID) was to be maintained at a stable level (Ͻ10% increase/decrease of baseline dose). Use of rescue medication (increased insulin dose, oral medication) was at the investigator's discretion if the patient met certain criteria; such patients remained in the study.
Primary end point was the change from baseline to study end (day 336) in A1C. Secondary end points included changes in glycemic parameters (fasting plasma glucose, patients meeting A1C Ͻ7 and Ͻ6.5% targets, introduction of rescue medication, and change in mean TDID [MTDID] ), proportion of patients with decreased TDID (Ͼ10% of baseline dose), lipid parameters (HDL cholesterol, triglycerides, LDL cholesterol, total cholesterol, and total-to-HDL cholesterol ratio), body weight, and waist circumference. In addition to standard safety assessments, a scripted neurological and psychiatric questionnaire was completed at each visit (see online appendix [available at http://care. diabetesjournals.org/cgi/content/full/dc09-0455/DC1]).
RESULTS -In total, 366 patients were randomized (n ϭ 179 rimonabant; n ϭ 187 placebo), and 284 completed treatment (134 [74.9%] rimonabant; 150 [80.2%] placebo). Demographic and baseline clinical characteristics were similar across groups (supplementary Table  1 ). At week 48, rimonabant produced significantly greater reductions in A1C and fasting plasma glucose levels versus placebo, and significantly more patients achieved target A1C levels (supplemen- Table 2 ). A1C levels decreased continuously with rimonabant without plateau (Fig. 1A) . Within both groups, higher baseline A1C levels correlated with greater absolute A1C reductions; between-group differences favored rimonabant within all baseline A1C categories (Fig. 1B) . Rimonabant resulted in a significantly greater change in MTDID than placebo (mean difference Ϫ2.90; P ϭ 0.0004), and more patients reduced MTDID by Ͼ10%. Significantly fewer patients receiving 
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rimonabant required rescue medication. Days with at least one nonsymptomatic hypoglycemic event were greater with rimonabant than placebo (2.34 vs. 1.18 days, respectively; P ϭ NS).
Significantly greater improvements with rimonabant versus placebo occurred in body weight (Fig. 1C) , waist circumference, HDL cholesterol, triglycerides, and total-to-HDL cholesterol ratio. No between-group differences were observed for total or LDL cholesterol changes. The overall incidence of treatment-emergent adverse events (TEAEs) was similar between groups (supplementary Table 3 ); there were slightly fewer serious TEAEs with rimonabant versus placebo. TEAEs were mild to moderate in intensity, generally occurred early in treatment, and resolved without further corrective therapy. Metabolism/ nutritional and psychiatric TEAEs occurred more frequently with rimonabant than placebo. Psychiatric disorders occurred in 31.3% of rimonabant-treated patients compared with 18.7% for placebo. Serious hypoglycemia was reported in four rimonabant patients versus two on placebo.
CONCLUSIONS -The ARPEGGIO study showed that 20 mg rimonabant significantly reduced A1C levels and improved multiple cardiometabolic risk factors in patients with type 2 diabetes receiving various types of insulin monotherapy, consistent with clinical trials of rimonabant in other type 2 diabetes populations (8, 11) .
Similar to previous studies and diabetes pharmacotherapy in general, A1C reductions were greatest in patients with highest baseline A1C (12) . The ARPEGGIO study was characterized by a higher mean baseline A1C than patients in the SERE-NADE and RIO-Diabetes studies (8, 11) , and a larger fall in A1C may have been expected. The result may have been affected by weight loss (although significant was less in this study and may have been mitigated by larger increases in glysuria) and reduced insulin dosing in the rimonabant group secondary to hypoglycemia.
Weight loss was less than that observed in other studies (8, 11) . Weight gain is often associated with insulin therapy. In addition, patients in the ARPEGGIO study (mean diabetes duration 14 years) were characterized by advanced ␤-cell loss and variable insulin resistance. Rimonabantinduced weight loss occurs through central effects in reducing food intake and through peripheral metabolic pathways (altered substrate utilization, changes in adiponectin, and changes in energy expenditure) (13) . This study showed that rimonabant facilitates weight loss in patients receiving insulin and may independently impact glucose, but the absolute change may be attenuated compared with nondiabetic patients or those receiving oral agents.
The safety profile of rimonabant was concordant with studies in similar patient populations (8, 11) . Patients with a history of psychiatric illness (depression/ anxiety) were not excluded. Few serious psychiatric adverse events occurred (one case of suicidal ideation with rimonabant), consistent with previous studies involving patients with a psychiatric illness history (14) . The ARPEGGIO study further supports the endocannabinoid system as a therapeutic target for overweight and glycemia. Further evaluation of this system is needed to achieve effective and well-tolerated agents.
